| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (NCT04108858) | National Cancer Institute (NCI) | 2021-05-20 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (NCT04457596) | Alliance for Clinical Trials in Oncology | 2021-03-02 |
| Nipple Aspirate Fluid in Detecting Breast Cancer (NCT03715959) | Ohio State University Comprehensive Cancer Center | 2020-12-10 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (NCT04351230) | Academic and Community Cancer Research United | 2020-11-11 |
| Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer (NCT04249622) | Mayo Clinic | 2020-09-18 |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer (NCT04517838) | Mayo Clinic | 2020-07-31 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (NCT04120246) | Veana Therapeutics | 2020-04-08 |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (NCT03368729) | University of Alabama at Birmingham | 2019-09-06 |
| A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2 (NCT03908749) | Anhui Provincial Hospital | 2019-04-10 |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 (NCT03630809) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-10 |
| T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (NCT03530696) | University of Arizona | 2018-12-06 |
| HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (NCT03387553) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-06 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases (NCT03500380) | RemeGen Co., Ltd. | 2018-04-24 |
| Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (NCT03384914) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-19 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer (NCT03364348) | George W. Sledge Jr. | 2017-10-30 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (NCT03179904) | Mayo Clinic | 2017-08-03 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579) | M.D. Anderson Cancer Center | 2017-01-20 |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (NCT02827877) | City of Hope Medical Center | 2016-07-15 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209) | National Cancer Institute (NCI) | 2014-02-18 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868) | National Cancer Institute (NCI) | 2012-12-06 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer (NCT00005970) | National Cancer Institute (NCI) | 2000-05-19 |